Literature DB >> 16823030

Early postnatal plasticity in neocortex of Fmr1 knockout mice.

Niraj S Desai1, Tanya M Casimiro, Stephen M Gruber, Peter W Vanderklish.   

Abstract

Fragile X syndrome is produced by a defect in a single X-linked gene, called Fmr1, and is characterized by abnormal dendritic spine morphologies with spines that are longer and thinner in neocortex than those from age-matched controls. Studies using Fmr1 knockout mice indicate that spine abnormalities are especially pronounced in the first month of life, suggesting that altered developmental plasticity underlies some of the behavioral phenotypes associated with the syndrome. To address this issue, we used intracellular recordings in neocortical slices from early postnatal mice to examine the effects of Fmr1 disruption on two forms of plasticity active during development. One of these, long-term potentiation of intrinsic excitability, is intrinsic in expression and requires mGluR5 activation. The other, spike timing-dependent plasticity, is synaptic in expression and requires N-methyl-d-aspartate receptor activation. While intrinsic plasticity was normal in the knockout mice, synaptic plasticity was altered in an unusual and striking way: long-term depression was robust but long-term potentiation was entirely absent. These findings underscore the ideas that Fmr1 has highly selective effects on plasticity and that abnormal postnatal development is an important component of the disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16823030     DOI: 10.1152/jn.00221.2006

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  59 in total

1.  Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome.

Authors:  Aparna Suvrathan; Charles A Hoeffer; Helen Wong; Eric Klann; Sumantra Chattarji
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  Delayed stabilization of dendritic spines in fragile X mice.

Authors:  Alberto Cruz-Martín; Michelle Crespo; Carlos Portera-Cailliau
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

Review 3.  Fragile X syndrome: the GABAergic system and circuit dysfunction.

Authors:  Scott M Paluszkiewicz; Brandon S Martin; Molly M Huntsman
Journal:  Dev Neurosci       Date:  2011-09-21       Impact factor: 2.984

4.  Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome.

Authors:  Tao Su; Hong-Xing Fan; Tao Jiang; Wei-Wen Sun; Wei-Yi Den; Mei-Mei Gao; Sheng-Qiang Chen; Qi-Hua Zhao; Yong-Hong Yi
Journal:  Psychopharmacology (Berl)       Date:  2010-12-23       Impact factor: 4.530

Review 5.  Taking STEPs forward to understand fragile X syndrome.

Authors:  Susan M Goebel-Goody; Paul J Lombroso
Journal:  Results Probl Cell Differ       Date:  2012

Review 6.  Toward fulfilling the promise of molecular medicine in fragile X syndrome.

Authors:  Dilja D Krueger; Mark F Bear
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

Review 7.  Role of hippocampal NMDA receptors in a mouse model for fragile X mental retardation syndrome.

Authors:  Thomas Mittmann
Journal:  J Physiol       Date:  2009-02-15       Impact factor: 5.182

Review 8.  The state of synapses in fragile X syndrome.

Authors:  Brad E Pfeiffer; Kimberly M Huber
Journal:  Neuroscientist       Date:  2009-03-26       Impact factor: 7.519

9.  Fragile X Mental Retardation Protein Bidirectionally Controls Dendritic Ih in a Cell Type-Specific Manner between Mouse Hippocampus and Prefrontal Cortex.

Authors:  Federico Brandalise; Brian E Kalmbach; Preeti Mehta; Olivia Thornton; Daniel Johnston; Boris V Zemelman; Darrin H Brager
Journal:  J Neurosci       Date:  2020-05-28       Impact factor: 6.167

10.  Homeostatic responses fail to correct defective amygdala inhibitory circuit maturation in fragile X syndrome.

Authors:  Rebecca L Vislay; Brandon S Martin; Jose Luis Olmos-Serrano; Sebila Kratovac; David L Nelson; Joshua G Corbin; Molly M Huntsman
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.